Markets

Otonomy prices upsized IPO at $16, the high end of the range

An image of a person holding up a graph
Credit: Shutterstock photo

Otonomy, a late-stage biotech developing sustained-exposure treatments for ear diseases, raised $100 million in an upsized IPO by offering 6.3 million shares at $16.00, at the high end of the range of $14.00 to $16.00. The company originally planned to offer 5.3 million shares. Otonomy plans to list on the NASDAQ under the symbol OTIC. Otonomy initially filed confidentially on 6/5/2014. J.P. Morgan and BofA Merrill Lynch acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More